{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-200247","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.010992+00:00","generated_at":"2026-05-31T09:21:15.994754+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica Q2 2024: YCANTH revenue $4.9M; net loss $17.2M; positive Phase 2 BCC data","bullets":["Net product revenue of $4.9M from YCANTH; net loss $17.2M ($0.37/sh) vs $11.0M ($0.24/sh) in Q2 2023.","Cash and equivalents $31.9M; expects runway into Q1 2025.","Phase 2 VP-315: 51% complete histologic clearance of basal cell carcinoma; no serious adverse events.","Permanent J-Code for YCANTH effective Apr 1; settlement with Dormer Labs to stop unapproved cantharidin sales in US.","Amended Torii agreement: equal cost split for Phase 3 common warts trial; $8M milestone at first Japan patient dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-200247","json":"https://secwatch.observer/filing/0001193125-24-200247.json","markdown":"https://secwatch.observer/filing/0001193125-24-200247.md","text":"https://secwatch.observer/filing/0001193125-24-200247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524200247/0001193125-24-200247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524200247/d857642d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:21:15.994754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}